← Back to Search

Decision Support Tool for Blood Cancers (DISCOVERY Trial)

N/A
Recruiting
Led By Daniel R Richardson, MD, MA, MSc
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to determine if a new decision support tool called PRIME can help improve patient-doctor agreement on treatment decisions by providing personalized feedback based on the patient's values and preferences.

Who is the study for?
This trial is for adults aged 60 or older who are new to the hematology/oncology clinic and need treatment decisions for conditions like lymphoma, leukemia, or multiple myeloma. Participants must be able to understand the study and give consent.
What is being tested?
The DISCOVERY trial is testing PRIME, a decision support tool designed to help patients with blood cancers make treatment choices that align with their personal values by providing feedback to both patients and doctors.
What are the potential side effects?
Since PRIME is a decision support tool rather than a medication, it does not have physical side effects. However, participants may experience emotional or psychological impacts from discussing their values and preferences.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference in COLLABORATE scores between arms
Secondary study objectives
Difference in COLLABORATE scores between arms in a subgroup of patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PRIME interventionExperimental Treatment1 Intervention
Receive the PRIME intervention.
Group II: Usual CareActive Control1 Intervention
Receive usual care.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
363 Previous Clinical Trials
91,508 Total Patients Enrolled
25 Trials studying Lymphoma
19,463 Patients Enrolled for Lymphoma
Daniel R Richardson, MD, MA, MScPrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center
~333 spots leftby Sep 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top